Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)

被引:13
|
作者
Mata, Guillaume [1 ]
Miles, Dillon H. [1 ]
Drew, Samuel L. [1 ]
Fournier, Jeremy [1 ]
Lawson, Kenneth, V [1 ]
Mailyan, Artur K. [1 ]
Sharif, Ehesan U. [1 ]
Yan, Xuelei [1 ]
Beatty, Joel W. [1 ]
Banuelos, Jesus [1 ]
Chen, Jie [1 ]
Ginn, Elaine [1 ]
Chen, Ada [1 ]
Gerrick, Kimberline Y. [1 ]
Pham, Amber T. [1 ]
Wong, Kent [1 ]
Soni, Divyank [1 ]
Dhanota, Puja [1 ]
Shaqfeh, Stefan G. [1 ]
Meleza, Cesar [1 ]
Narasappa, Nell [1 ]
Singh, Hema [1 ]
Zhao, Xiaoning [1 ]
Jin, Lixia [1 ]
Schindler, Ulrike [1 ]
Walters, Matthew J. [1 ]
Young, Stephen W. [1 ]
Walker, Nigel P. [1 ]
Leleti, Manmohan Reddy [1 ]
Powers, Jay P. [1 ]
Jeffrey, Jenna L. [1 ]
机构
[1] Arcus Biosci Inc, Hayward, CA 94545 USA
关键词
QUANTITATIVE ASSESSMENT; PI3K INHIBITORS; LIPOPHILICITY; PERMEABILITY; INFLAMMATION; DISCOVERY;
D O I
10.1021/acs.jmedchem.1c01153
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Phosphoinositide-3-kinase gamma (PI3K gamma) is highly expressed in immune cells and promotes the production and migration of inflammatory mediators. The inhibition of PI3K. has been shown to repolarize the tumor immune microenvironment to a more inflammatory phenotype, thereby controlling immune suppression in cancer. Herein, we report the structure-based optimization of an early lead series of pyrazolopyrimidine isoindolinones, which culminated in the discovery of highly potent and isoform-selective PI3K gamma inhibitors with favorable drug-like properties. X-ray cocrystal structure analysis, molecular docking studies, and detailed structure- activity relationship investigations resulted in the identification of the optimal amide and isoindolinone substituents to achieve a desirable combination of potency, selectivity, and metabolic stability. Preliminary in vitro studies indicate that inhibition of PI3K gamma with compound 56 results in a significant immune response by increasing pro-inflammatory cytokine gene expression in M1 macrophages.
引用
收藏
页码:1418 / 1444
页数:27
相关论文
共 50 条
  • [31] Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform
    Heffron, Timothy P.
    Wei, BinQing
    Olivero, Alan
    Staben, Steven T.
    Tsui, Vickie
    Do, Steven
    Dotson, Jennafer
    Folkes, Adrian J.
    Goldsmith, Paul
    Goldsmith, Richard
    Gunzner, Janet
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Shuttleworth, Stephen
    Sutherlin, Daniel P.
    Wan, Nan Chi
    Wang, Shumei
    Wiesmann, Christian
    Zhu, Bing-Yan
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (22) : 7815 - 7833
  • [32] Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα) -: Functions of lipid kinase-deficient PI3Kα in signaling
    Pirola, L
    Zvelebil, MJ
    Bulgarelli-Leva, G
    Van Obberghen, E
    Waterfield, MD
    Wymann, MP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (24) : 21544 - 21554
  • [33] Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
    Nishimura, Nobuko
    Siegmund, Aaron
    Liu, Longbin
    Yang, Kevin
    Bryan, Marian C.
    Andrews, Kristin L.
    Bo, Yunxin
    Booker, Shon K.
    Caenepeel, Sean
    Freeman, Daniel
    Liao, Hongyu
    McCarter, John
    Mullady, Erin L.
    San Miguel, Tisha
    Subramanian, Raju
    Tamayo, Nuria
    Wang, Ling
    Whittington, Douglas A.
    Zalameda, Leeanne
    Zhang, Nancy
    Hughes, Paul E.
    Norman, Mark H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (13) : 4735 - 4751
  • [34] Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation
    Kawada, Hatsuo
    Ebiike, Hirosato
    Tsukazaki, Masao
    Nakamura, Mitsuaki
    Morikami, Kenji
    Yoshinari, Kiyoshi
    Yoshida, Miyuki
    Ogawa, Kotaro
    Shimma, Nobuo
    Tsukuda, Takuo
    Ohwada, Jun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (03) : 673 - 678
  • [35] Phosphoinositide 3-kinase (PI3K) classes: From cell signaling to endocytic recycling and autophagy
    Safaroghli-Azar, Ava
    Sanaei, Mohammad-Javad
    Pourbagheri-Sigaroodi, Atieh
    Bashash, Davood
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 953
  • [36] Phosphoinositide 3-kinase (PI3K) plays a critical role in physiological hypertrophy but not in pathological hypertrophy
    McMullen, JR
    Shioi, T
    Zhang, L
    Izumo, S
    CIRCULATION, 2002, 106 (19) : 58 - 58
  • [37] Discovery of INCB098377: a potent inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ)
    Arias, Diana A.
    Douglass, Stephen
    Truong, Lisa
    Wang, Qian
    Wang, Kathy H.
    Yang, Gengjie
    Hansbury, Michael
    O'Connor, Sybil
    Bowman, Kevin
    Collins, Robert
    Stubbs, Matthew
    Hall, Leslie
    Stevens, Christina
    Maddage, Christopher
    Douty, Brent
    Covington, Maryanne
    Leffet, Lynn
    Yue, Eddy
    Combs, Andrew
    Kim, Sunkyu
    Shin, Niu
    Koblish, Holly
    Hess, Rodrigo
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Up-regulated phosphoinositide 3-kinase γ (PI3Kγ) promotes breast cancer metastasis
    Xie, Yan
    Kirui, Joseph K.
    Jiang, Haihong
    Deng, Caishu
    Tu, Yaping
    FASEB JOURNAL, 2010, 24
  • [39] Design, synthesis and structure-activity relationship study of piperazinone-containing thieno [3,2-d] pyrimidine derivatives as new PI3Kδ inhibitors
    Wang, Ning-Yu
    Zuo, Wei-Qiong
    Hu, Rong
    Wang, Wan-Li
    Zhu, Yong-Xia
    Xu, Ying
    Yu, Luo-Ting
    Liu, Zhi-Hao
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (20)
  • [40] PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors
    Croessmann, Sarah
    Sheehan, Jonathan H.
    Lee, Kyung-min
    Sliwoski, Gregory
    He, Jie
    Nagy, Rebecca
    Riddle, David
    Mayer, Ingrid A.
    Balko, Justin M.
    Lanman, Richard
    Miller, Vincent A.
    Cantley, Lewis C.
    Meiler, Jens
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2018, 24 (06) : 1426 - 1435